Skip to Content
Søk Menu

Post hoc analysis shows a clear correlation between high expression of PDL1 and efficacy of cemiplimab

At WCLC 2020, Dr Saadettin Kilickap reported the results of a post hoc analysis of the phase III EMPOWER-Lung 1 trial evaluating cemiplimab vs platinum-doublet chemotherapy as a frontline treatment in 437 patients with advanced NSCLC with a PD-L1 level ≥ 50%.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relateret indhold

Pembrolizumab plus chemotherapy provided durable clinical benefit in patients with metastatic squamous NSCLC

/ Martin Reck
NSCLCWCLC20 Play the Video 8:48

Pembrolizumab with chemo-radiation therapy showed promising antitumor activity in unresectable, locally advanced, stage III NSCLC

/ Martin Reck
NSCLCWCLC20 Play the Video 7:17

Opløftende data for patienter med recidiverende malign mesotheliom

/ Jens Benn Sørensen
WCLC20 Play the Video 10:55

WCLC2020: Pembrolizumab significantly improved 5-year survival in patients with previously treated advanced NSCLC

/ Roy S. Herbst
NSCLCWCLC20 Play the Video 2:25

WCLC2020: COVID-19 outcomes in patients with thoracic malignancies

/ Umit Tapan
COVID-19WCLC20 Play the Video 16:35

12 months data from KEYNOTE-799 confirm promising response rates with pembrolizumab in combination with chemo-radiation therapy for locally advanced NSCLC

/ BestPractice Nordic
NSCLCWCLC20

Promising results with neoadjuvant atezolizumab for stage IB-IIIB NSCLC

/ BestPractice Nordic
NSCLCWCLC20

WCLC2020: Pre-operative treatment with atezolizumab in untreated stage IB-IIIB resectable NSCLC

/ Jay M. Lee
NSCLCWCLC20 Play the Video 10:38

Nivolumab monotherapy is an effective treatment option for recurrent malignant mesothelioma

/ BestPractice Nordic
WCLC20
Back to top